# Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy

> **NCT06888661** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Guangzhou Jiayin Biotech Ltd** · enrollment: 4 (estimated)

## Conditions studied

- Spinal Muscular Atrophy (SMA)

## Interventions

- **BIOLOGICAL:** EXG001-307 injection

## Key facts

- **NCT ID:** NCT06888661
- **Lead sponsor:** Guangzhou Jiayin Biotech Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-03-10
- **Primary completion:** 2026-03
- **Final completion:** 2026-12-30
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888661, "Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06888661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*